ROLE OF CORONARY PRESSURE & FFR IN MULTIVESSEL DISEASE

Angioplasty Summit TCT ASIA Seoul, Korea, april 24th, 2008





Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands

A rather common patient in our cath lab today......

- 72-year-old male, stable angina class 3
- small non-STEMI 3 weeks earlier, no diagnostic Δ-ECG
- residual angina class 2-3
- positive exercise stress test


Coronary angiography






LCA

FAME STUDY patient # 1249 June 25th, 2007





RCA

FAME STUDY patient # 1249 June 25th, 2007

A rather common patient in our cath lab today......

- 72-year-old male, stable angina class 3
- small non-STEMI 3 weeks earlier, no diagnostic Δ-ECG
- residual angina class 2-3
- positive exercise stress test

Coronary angiography

- 50% LAD artery
- 50% Intermediate branch
- 90% LCX artery
- 70 % RCA proximal
- 50% RCA mid

A rather common patient in our cath lab today......

BUT HOW TO PROCEED.....???

It is not the question <u>IF</u> stenting is indicated, but <u>WHERE</u> and <u>HOW MANY</u>

Several scenario's

- If you are a very practical dedicated interventionalist:
 - "stent the LCX and see what happens afterwards"
- If you are a more agressive interventionalist and believe that every lesion should be treated:
 - "nice lesions to fix, let's place 3 or 4 stents"

(expensive, maybe unnecessary or even increasing risk, but neither the doctor, nor the patient will ever know)

- If you are strictly following guidelines (and not too familiar with FFR):
 - "let's do a MIBI-SPECT first"

(expensive, time consuming, not very practical)

Which lesions should be stented?

IMPORTANT ISSUE TO KEEP IN MIND

In patients with coronary artery disease, the most important factor with respect to <u>both</u>

- functional class (symptoms)
- and prognosis (outcome)

Is the presence and extent of inducible ischemia


EVIDENCE-BASED MEDICINE:


- PCI of "culprit" lesions (associated with reversible ischemia) makes sense and improves symptoms and sometimes also <u>outcome</u>
- PCI of non-ischemic lesions has <u>no benefit</u>, is <u>not</u> <u>superior to medical treatment</u>, potentially harmful, and <u>unnecessary expensive</u>
- FFR is the gold standard for assessment of ischemia in the catheterization lab

→ Let's measure FFR

DEFER study; JACC 2007 ACIP study; Circulation 1997 Courage trial; NEJM 2007

During Maximal Vasodilatation





Threshold value of FFR to detect significant stenosis




FFR is the *only* functional index which has ever been validated versus a **true gold standard**. (*Prospective multi-testing Bayesian methodology*)


ALL studies ever performed in a wide variety of clinical & angiographic conditions, found threshold between 0.75 and 0.80

Sensitivity: 90%


Specificity: 100%


N Engl J Med 1996; 334:1703-1708





LCA RAO 30/20 view








PW in LAD artery















LCX after stenting (Endeavour 3.5 x 12)









RCA





Pressure Wire in RCA



LESSONS FROM THIS PATIENT:

- only 1 stent necessary; cost-savings of Euro 3300,-
- if treatment was based upon angio and performed by "more agresssive" interventionalist (or had been randomized to angio-guided arm of FAME study), at least 3 and maybe 4 or 5 stents would have been placed, which would have increased risk and would have been unnecessary expensive


ANGIO-GUIDED MULTIVESSEL PCI versus

FFR-GUIDED (= ischemia-guided) MULTIVESSEL PCI

What is better?

FAME study has to answer the question decisively

(FFR-guided ~ better, cheaper, quicker)



FFR-guided vs. Angio-guided multivessel PCI (125 patients) (event-free survival after 30 months)

Leesar et al, JACC 2005



FAME STUDY

Functional vs Angiographic Multivessel Evaluation

Prospective and randomized multicenter trial in 1000 patients undergoing multivessel PCI


angio-guided: all lesions > 50% DES-stented

FFR-guided: DES-stents in lesions with FFR < 0.80

Endpoints: outcome, symptoms, cost-efficiency

20 centers in USA and Europe Inclusion has been completed now Follow-up completed at TCT 2008

Flow Chart





FAME STUDY

Functional vs Angiographic Multivessel Evaluation

- → Prospective and randomized multicenter trial in 1000 patients undergoing multivessel PCI
- Hypothesis: FFR-guided multivessel PCI is superior to angio-guided multivessel PCI

FOLLOW-UP WILL BE COMPLETED ON SEPTEMBER 27th

COMPLETE RESULTS AT TCT 2008

FAME: Preliminary baseline data – Europe (1)

~ 60% of all screened patients were included !!!

	FFR-group (n=368)	Angio-group (n=352)
Age (yrs)	66	64
Male	74%	70%
CCS Class	2,4	2,4
Diabetes	20%	23%
LV ejection fraction	57%	58%
Ischemia detected	40%	42%

FAME: Preliminary baseline data - Europe

	FFR-group (n=368)	Angio-group (n=352)
Acute chest pain with EKG∆	14%	19%
Acute chest pain no EKG∆	12%	12%
Previous PCI	27%	24%
Previous MI	35%	35%
Lesions indicated	2,8	2,7
Stents per patient	1,9	2,9

FAME: Preliminary baseline data - Europe

	FFR-group (n=368)	Angio-group (n=352)
QCA: Stenosis %	58,8	56,3
QCA: Ref. diameter (mm)	2,46	2,41
Procedure time (min)	67	66
Contrast agent used (ml)	263	293

NS

P<0.01

FFR IN MULTIVESSEL DISEASE

SUMMARY

Coronary pressure measurement is a helpful, easy, and relatively cheap tool in multivessel disease to:

- select the "culprit" spots and segments out of the many abnormalities which are often present
- discrimate if PCI of a particular spot or segment makes sense
- evaluate the result of stenting with prognostic implications
- and to avoid additional interventions which increase risk without benefit for the patient

Complete vs Incomplete Revascularization:

What was wrong the wrong concept in the (mostly <u>retrospective</u>) studies performed so far ?!

e.g. ARTS-studies:

30% incomplete revascularization, but....

"arbitrary" choice of no revascularization, or even worse: no revascularization because of technical difficulties → considerable number of the non-revascularized lesions were ischemic lesions

Whereas among the treated lesions, quite a bit of non-ischemic lesions must have been stented


Does routine measurement of FFR influence our strategy in MVD ??

- Study by Dr F. Mendes, Cabo Frio, Brasil
- all consecutive patients with MVD during 3 months (september december 2004): 195 patients
- revascularization strategy based upon angio assessed by 3 operators
- FFR measured in all stenoses and used for final decision making
- change in strategy in 34% of lesions and 45 % of patients

Clinical Outcome According to the Compliance with FFR

- 409 patients + FFR measurements
- Clinical outcome at one year

MACE Rate at 1 y (%)




Clinical Outcome According to the Compliance with FFR

Legalery et al Eur Heart J 2005

- 409 patients + FFR measurements
- Clinical outcome at one year

MACE Rate at 1 y (%)



FFR < 0.80 : PCI results in 3 x lower event rate FFR > 0.80 : PCI results in 3 x higher event rate

COURAGE TRIAL: SOME CRITICAL NOTES

- How representative is the Courage Trial?
 only 6% of eligible patients were truly included
- Two-way negative bias for PCI group:
 - In PCI group, selection of lesions to be stented was on the basis of angiography → at least 30% unnecessary stents, which unfavourably affects prognosis
 - 2. In PCI group, also a number of ischemic lesions must have been missed, which also unfavouraby affects prognosis (ACIP-trial, Circulation 1996)

In terms of functional class the PCI group did better than the medical group, particularly in patients with proven ischemia!